Effect of clofibrate on plasma glucose and serum immunoreactive insulin in patients with hyperlipoproteinemia.
D000328:Adult; D000368:Aged; D000941:Antigens; D001786:Blood Glucose / Q000378:metabolism*; D001796:Blood Protein Disorders / Q000097:blood*; D001835:Body Weight; D002994:Clofibrate / Q000494:pharmacology*; D005230:Fatty Acids, Nonesterified / Q000097:blood*; D005260:Female; D005951:Glucose Tolerance Test; D006207:Half-Life; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood; D006949:Hyperlipidemias / Q000097:blood; D007328:Insulin / Q000096:biosynthesis / Q000097:blood* / Q000378:metabolism; D000078790:Insulin Secretion; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010179:Pancreas / Q000378:metabolism; D012044:Regression Analysis; D014280:Triglycerides / Q000097:blood
D000941:Antigens; D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D008074:Lipoproteins; D014280:Triglycerides; D002994:Clofibrate